Stocks and Investing
Stocks and Investing
Fri, September 6, 2024
[ Fri, Sep 06th 2024
] - WOPRAI
[ Fri, Sep 06th 2024
] - WOPRAI
[ Fri, Sep 06th 2024
] - WOPRAI
[ Fri, Sep 06th 2024
] - WOPRAI
[ Fri, Sep 06th 2024
] - WOPRAI
[ Fri, Sep 06th 2024
] - WOPRAI
[ Fri, Sep 06th 2024
] - WOPRAI
[ Fri, Sep 06th 2024
] - WOPRAI
[ Fri, Sep 06th 2024
] - WOPRAI
[ Fri, Sep 06th 2024
] - WOPRAI
[ Fri, Sep 06th 2024
] - WOPRAI
[ Fri, Sep 06th 2024
] - WOPRAI
[ Fri, Sep 06th 2024
] - WOPRAI
[ Fri, Sep 06th 2024
] - WOPRAI
[ Fri, Sep 06th 2024
] - WOPRAI
[ Fri, Sep 06th 2024
] - WOPRAI
[ Fri, Sep 06th 2024
] - WOPRAI
[ Fri, Sep 06th 2024
] - WOPRAI
[ Fri, Sep 06th 2024
] - WOPRAI
[ Fri, Sep 06th 2024
] - WOPRAI
[ Fri, Sep 06th 2024
] - WOPRAI
[ Fri, Sep 06th 2024
] - WOPRAI
[ Fri, Sep 06th 2024
] - WOPRAI
[ Fri, Sep 06th 2024
] - WOPRAI
[ Fri, Sep 06th 2024
] - WOPRAI
[ Fri, Sep 06th 2024
] - WOPRAI
[ Fri, Sep 06th 2024
] - WOPRAI
[ Fri, Sep 06th 2024
] - WOPRAI
[ Fri, Sep 06th 2024
] - WOPRAI
Chris Schott Upgraded (AMRX) to Hold and Held Target at $9 on, Sep 6th, 2024
Chris Schott of JP Morgan, Upgraded "Amneal Pharmaceuticals, Inc." (AMRX) to Hold and Held Target at $9 on, Sep 6th, 2024.
Chris has made no other calls on AMRX in the last 4 months.
There are 3 other peers that have a rating on AMRX. Out of the 3 peers that are also analyzing AMRX, 0 agree with Chris's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Chris
- Balaji Prasad of "Barclays" Maintained at Buy with Increased Target to $10 on, Tuesday, August 13th, 2024
- Les Sulewski of "Truist Securities" Maintained at Strong Buy with Increased Target to $10 on, Monday, August 12th, 2024
- Nathan Rich of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $8 on, Monday, May 6th, 2024
Contributing Sources